Cargando…
Biologically responsive carrier-mediated anti-angiogenesis shRNA delivery for tumor treatment
Small interfering RNA (siRNA) has increased the hope for highly-efficient treatment of gene-related diseases. However, the stable and efficient delivery of therapeutic nucleic acids is a prerequisite for the successful clinical translation of RNA interfering therapy. To achieve this, we condensed th...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069559/ https://www.ncbi.nlm.nih.gov/pubmed/27759095 http://dx.doi.org/10.1038/srep35661 |
_version_ | 1782460959101550592 |
---|---|
author | Che, Junyi Tao, Anqi Chen, Shun Li, Xiaoming Zhao, Yi Yuan, Weien |
author_facet | Che, Junyi Tao, Anqi Chen, Shun Li, Xiaoming Zhao, Yi Yuan, Weien |
author_sort | Che, Junyi |
collection | PubMed |
description | Small interfering RNA (siRNA) has increased the hope for highly-efficient treatment of gene-related diseases. However, the stable and efficient delivery of therapeutic nucleic acids is a prerequisite for the successful clinical translation of RNA interfering therapy. To achieve this, we condensed the low molecular weight polyethyleneimine (PEI, Mw < 2000) with 2,6-pyridinedicarboxaldehyde (PDA) to synthesize a biologically responsive and degradable cationic polymer (abbreviated to PDAPEI) which was utilized as a gene vector for the delivery of a VEGF-A shRNA expression plasmid DNA (pDNA). The resulting electrostatic interaction between PDAPEI and pDNA led to the self-assembly of nanoscale polyplexes with suitable particle size and stable zeta potential. The PDAPEI/pDNA polyplexes demonstrated an outstanding gene transfection and silencing efficiency at 30 w/w ratio, as well as negligible cytotoxicity. Also, the designed polymer showed no stimulation to the innate immune system. Moreover, compared with PEI 25 KDa, the polyplexes accomplished comparatively better anti-angiogenesis efficacy, which resulted in the inhibition of tumor growth in subcutaneous tumor mice models. In conclusion, PDAPEI has great potential to be a gene delivery vector for cancer therapy. |
format | Online Article Text |
id | pubmed-5069559 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-50695592016-10-26 Biologically responsive carrier-mediated anti-angiogenesis shRNA delivery for tumor treatment Che, Junyi Tao, Anqi Chen, Shun Li, Xiaoming Zhao, Yi Yuan, Weien Sci Rep Article Small interfering RNA (siRNA) has increased the hope for highly-efficient treatment of gene-related diseases. However, the stable and efficient delivery of therapeutic nucleic acids is a prerequisite for the successful clinical translation of RNA interfering therapy. To achieve this, we condensed the low molecular weight polyethyleneimine (PEI, Mw < 2000) with 2,6-pyridinedicarboxaldehyde (PDA) to synthesize a biologically responsive and degradable cationic polymer (abbreviated to PDAPEI) which was utilized as a gene vector for the delivery of a VEGF-A shRNA expression plasmid DNA (pDNA). The resulting electrostatic interaction between PDAPEI and pDNA led to the self-assembly of nanoscale polyplexes with suitable particle size and stable zeta potential. The PDAPEI/pDNA polyplexes demonstrated an outstanding gene transfection and silencing efficiency at 30 w/w ratio, as well as negligible cytotoxicity. Also, the designed polymer showed no stimulation to the innate immune system. Moreover, compared with PEI 25 KDa, the polyplexes accomplished comparatively better anti-angiogenesis efficacy, which resulted in the inhibition of tumor growth in subcutaneous tumor mice models. In conclusion, PDAPEI has great potential to be a gene delivery vector for cancer therapy. Nature Publishing Group 2016-10-19 /pmc/articles/PMC5069559/ /pubmed/27759095 http://dx.doi.org/10.1038/srep35661 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Che, Junyi Tao, Anqi Chen, Shun Li, Xiaoming Zhao, Yi Yuan, Weien Biologically responsive carrier-mediated anti-angiogenesis shRNA delivery for tumor treatment |
title | Biologically responsive carrier-mediated anti-angiogenesis shRNA delivery for tumor treatment |
title_full | Biologically responsive carrier-mediated anti-angiogenesis shRNA delivery for tumor treatment |
title_fullStr | Biologically responsive carrier-mediated anti-angiogenesis shRNA delivery for tumor treatment |
title_full_unstemmed | Biologically responsive carrier-mediated anti-angiogenesis shRNA delivery for tumor treatment |
title_short | Biologically responsive carrier-mediated anti-angiogenesis shRNA delivery for tumor treatment |
title_sort | biologically responsive carrier-mediated anti-angiogenesis shrna delivery for tumor treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069559/ https://www.ncbi.nlm.nih.gov/pubmed/27759095 http://dx.doi.org/10.1038/srep35661 |
work_keys_str_mv | AT chejunyi biologicallyresponsivecarriermediatedantiangiogenesisshrnadeliveryfortumortreatment AT taoanqi biologicallyresponsivecarriermediatedantiangiogenesisshrnadeliveryfortumortreatment AT chenshun biologicallyresponsivecarriermediatedantiangiogenesisshrnadeliveryfortumortreatment AT lixiaoming biologicallyresponsivecarriermediatedantiangiogenesisshrnadeliveryfortumortreatment AT zhaoyi biologicallyresponsivecarriermediatedantiangiogenesisshrnadeliveryfortumortreatment AT yuanweien biologicallyresponsivecarriermediatedantiangiogenesisshrnadeliveryfortumortreatment |